These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 10607708

  • 1. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
    Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF.
    Blood; 2000 Jan 01; 95(1):241-8. PubMed ID: 10607708
    [Abstract] [Full Text] [Related]

  • 2. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF.
    Arthritis Res; 2000 Jan 01; 2(2):154-64. PubMed ID: 11062606
    [Abstract] [Full Text] [Related]

  • 3. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, Signoret N, Rickinson AB, McMichael AJ.
    J Exp Med; 1995 Jun 01; 181(6):2221-8. PubMed ID: 7539044
    [Abstract] [Full Text] [Related]

  • 4. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
    Kuzushima K, Hayashi N, Kudoh A, Akatsuka Y, Tsujimura K, Morishima Y, Tsurumi T.
    Blood; 2003 Feb 15; 101(4):1460-8. PubMed ID: 12393434
    [Abstract] [Full Text] [Related]

  • 5. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.
    Blood; 2003 Mar 01; 101(5):1905-12. PubMed ID: 12411306
    [Abstract] [Full Text] [Related]

  • 6. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
    Meij P, Leen A, Rickinson AB, Verkoeijen S, Vervoort MB, Bloemena E, Middeldorp JM.
    Int J Cancer; 2002 May 01; 99(1):93-9. PubMed ID: 11948498
    [Abstract] [Full Text] [Related]

  • 7. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB.
    J Virol; 1993 Dec 01; 67(12):7428-35. PubMed ID: 7693972
    [Abstract] [Full Text] [Related]

  • 8. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ.
    J Immunother; 2007 Dec 01; 30(5):544-56. PubMed ID: 17589295
    [Abstract] [Full Text] [Related]

  • 9. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ.
    J Exp Med; 1996 Mar 01; 183(3):1215-28. PubMed ID: 8642263
    [Abstract] [Full Text] [Related]

  • 10. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
    Sohn DH, Sohn HJ, Lee HJ, Lee SD, Kim S, Hyun SJ, Cho HI, Cho SG, Lee SK, Kim TG.
    PLoS One; 2015 Mar 01; 10(5):e0127899. PubMed ID: 26023769
    [Abstract] [Full Text] [Related]

  • 11. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R, Burrows SR, Nicholls J, Poulsen LM.
    Eur J Immunol; 1998 Feb 01; 28(2):451-8. PubMed ID: 9521052
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 01; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 13. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
    Meij P, Bloemena E, Palmen N, Brink A, Vervoort MB, Meijer CJ, Middeldorp JM.
    Cell Immunol; 2001 Feb 25; 208(1):25-33. PubMed ID: 11277616
    [Abstract] [Full Text] [Related]

  • 14. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 25; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 15. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S.
    J Clin Oncol; 2005 Dec 10; 23(35):8942-9. PubMed ID: 16204009
    [Abstract] [Full Text] [Related]

  • 16. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, Johnson PJ.
    J Med Virol; 2002 Jul 10; 67(3):359-63. PubMed ID: 12116028
    [Abstract] [Full Text] [Related]

  • 17. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M.
    J Immunol; 2003 May 15; 170(10):5195-202. PubMed ID: 12734367
    [Abstract] [Full Text] [Related]

  • 18. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D, Storkus W, Zeevi A, Patterson K, Logar A, Rowe D, Nalesnik MA, Fung JJ, Rao AS.
    Transplantation; 2000 Nov 27; 70(10):1507-15. PubMed ID: 11118098
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 27; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q, Pollok KE, Burton RL, Dai LJ, Britt W, Emanuel DJ, Lucas KG.
    Blood; 1999 Nov 01; 94(9):3242-50. PubMed ID: 10556213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.